07
2019
-
12
Huaiqihuang Granules for the Treatment of CKD3 Primary Glomerulonephritis Initiated Meeting Held in Dalian
On the morning of December 7, 2019, the first affiliated Hospital of Dalian Medical University sponsored the "randomized double-blind double-simulation, positive parallel controlled multicenter clinical study of Huaiqihuang Granules in the treatment of CKD3 primary glomerulonephritis" held in Shangri-La Hotel, Dalian, which is the highest level of evidence-based medicine for Huaiqihuang Granules in the treatment of primary glomerulonephritis. The First Affiliated Hospital of Dalian Medical University is the team leader unit, Zero Krypton Technology (Beijing) Co., Ltd. is responsible for monitoring and implementation as a cooperative research organization, and the Public Health Center of Tongji Medical College of Huazhong University of Science and Technology is responsible for statistical analysis. Funding is provided by Hubei Chen Xiaoping Science and Technology Development Foundation.
Funding is provided by Hubei Chen Xiaoping Science and Technology Development Foundation.
The meeting was presided over by Professor Lin Hongli, the main researcher, and introduced the overall goal and significance of Huaiqihuang granule in the treatment of CDK3 primary glomerulonephritis. Chronic kidney disease is a common and frequently-occurring disease. At present, there is a lack of effective means in the treatment of patients with CDK3 and above. It is urgent to find effective interventions to delay and treat primary glomerulonephritis in patients with chronic kidney disease in stage 3. Therefore, it is very important to explore the safety and effectiveness of Huaiqihuang Granules in the treatment of primary glomerulonephritis. This clinical study is specially launched. Associate Professor Wang Dapeng of the First Affiliated Hospital of Dalian Medical University made a systematic introduction to the scheme. Dr. Ma Yilei, a statistician at Huazhong University of Science and Technology, gave a live demonstration of the central random system operation of drugs. Zero Krypton Technology's Lubaoting manager gave a detailed introduction to the project's inspection and quality control.
We wish the primary glomerulonephritis project in the national center smoothly, and a complete success.
More news
Address
1166 West Nanyuan Road, Qidong Economic Development Zone, Jiangsu Province
Telephone
Mobile website
Public Number
Copyright © 2024 Qidong Gaitianli Pharmaceutical Co., Ltd.